PMID: 6985831Jan 15, 1980Paper

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

Cancer
N I NissenJ F Holland

Abstract

The epipodophyllotoxin derivative VP 16--213 (NSC 141540) was studied by the Cancer and Leukemia Group B in a broad phase II trial at three dose levels: 60 mg/m2, 90 mg/m2, and 135 mg/m2 I.V. twice weekly. No correlation between dose of VP 16--213 and response frequency in a particular disease category could be demonstrated. Of the 382 patients, 8% obtained a complete (CR) or partial remission (PR), 8% showed improvement, and 14% had stable disease. By tumor type the best responses were obtained in lymphomas (8/31 CR + PR), uterus (2/9), prostate (1/5), rhabdomyosarcoma (2/6), neuroblastoma (2/4), colon/rectum (5/81), other gastrointestinal (4/32). In lung tumors, 4/80 patients obtained CR or PR. VP 16--213 has definite antineoplastic activity but the response frequency with the twice weekly schedule may be lower than that reported with other schedules.

References

Jul 1, 1977·Cancer·M RozencweigF M Muggia
Mar 1, 1973·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H Stähelin

❮ Previous
Next ❯

Citations

Sep 1, 1997·Seminars in Surgical Oncology·W M Brinkley, F M Torti
Jan 1, 1984·Journal of Cancer Research and Clinical Oncology·R M Canetta, S K Carter
May 1, 1995·Breast Cancer Research and Treatment·M BontenbalJ G Klijn
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·R S Miller, F M Torti
Feb 1, 1993·Journal of Neuro-oncology·M C Chamberlain
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A DonfrancescoG Deb
Jun 1, 1982·Cancer Treatment Reviews·H Schmoll
Feb 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J C GentetC Kalifa
Mar 14, 1985·The New England Journal of Medicine·P J O'DwyerR E Wittes
May 1, 1982·International Journal of Radiation Oncology, Biology, Physics·R J GieverG T Bowden
Apr 1, 1984·Urology·M S SolowayA Blatnik
Apr 1, 1984·International Journal of Radiation Oncology, Biology, Physics·G MorstynJ D Minna
Sep 1, 1983·Cancer Treatment Reviews·M T Bakowski, J C Crouch
Dec 1, 1983·Cancer Treatment Reviews·A G Pedersen, H H Hansen
Jan 1, 1989·Leukemia Research·E A StadtmauerR P Gale
Jun 1, 1982·Cancer Treatment Reviews·K Höffken
Jun 1, 1982·Cancer Treatment Reviews·A GoldhirschK W Brunner
Jun 1, 1982·Cancer Treatment Reviews·L M Itri, R J Gralla
Jun 1, 1982·Cancer Treatment Reviews·W F Jungi
Jun 28, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jakob K AnningaR Maarten Egeler
Sep 1, 1985·Cancer·H B NiellE E Smith
Aug 1, 1987·Cancer·A Yagoda
Apr 1, 1996·The Annals of Pharmacotherapy·R M HoetelmansJ H Beijnen
Jun 17, 2000·American Journal of Clinical Oncology·T SaphnerN J Robert

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.